

January 2016

**ANNUAL DECLARATION OF INTERESTS
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE
SCIENCE COMMITTEE
1 January 2014 – 31 December 2015**

GOLD participants disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations each year using the following definitions.

- 1. *Personal Benefits*** refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GOLD member benefits personally. This includes ongoing attendance at advisory board meetings.
- 2. *Shares*** refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GOLD member or family members (spouse/dependent children <18 yrs). The company is to be listed, not the number of shares.
- 3. *Non-Personal Interests*** refers to fees or grants paid to a GOLD Committee member (or the Department/Institution on behalf of a GOLD member) and used for research, education, equipment, salaries, etc.

For each category, items are included in one of two categories: payment or service is valued in excess of \$10,000 (US) but less than \$10,000 and payment or service is valued in excess of \$10,000. The information disclosed by each member of the Science Committee for the year 2015 is presented in an effort to be as transparent as possible. For more complete background about this process, see “Annual Declaration of Interests: Global Initiative for Chronic Obstructive Lung Disease (GOLD)” on the website at: <<http://www.goldcopd.org>>.

SUMMARY FOR YEAR 2015:

Alvar Agusti, Barcelona, Spain: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, Chiesi, Menarini, Novartis, TEVA. *Personal Benefits* >\$10,000: Almirall, GlaxoSmithKline. *Shares*: none. *Non-Personal Interests* >\$10,000: Almirall, GlaxoSmithKline, Merck Sharp & Dohme.

Antonio Anzueto, San Antonio, Texas, US: *Personal Benefits* <\$10,000: AstraZeneca, Novartis, Sunnovion. *Personal Benefits* >\$10,000: Boehringer-Ingelheim, GlaxoSmithKline. *Shares*: none. *Non-Personal Interests*: none.

Marc Decramer, Leuven Belgium: *Personal Benefits*: none. *Shares*: none. *Non-Personal Interests*: none.

Leonardo M. Fabbri, Modena, Italy: *Personal Benefits* <\$10,000: Almirall, Bayer, Boston Scientific, Guidotti, Kyorin, Merck Sharp & Dohme, Menarini, Mundipharma, Novartis, Pearl Therapeutics, Zambon. *Personal Benefits* >\$10,000: AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Takeda. *Shares*: none. *Non-Personal Interests* <\$10,000: Biofutura, Malesci. *Non-Personal Interests* >\$10,000: Almirall, AstraZeneca, Boehringer-Ingelheim,

Chiesi, Dompe, GlaxoSmithKline, Guidotti, Merck Sharp & Dohme, Menarini, Novartis, Pfizer, Takeda, Vree Health Italia, Zambon.

Fernando Martinez, Ann Arbor, Michigan: *Personal Benefits* <\$10,000: AstraZeneca, Bayer, Boehringer-Ingelheim, Clarion, Continuing Education, Falso MedEd Consulting, Haymarket, Integritas, Inthought Research, Kadman, Miller Communications, Pearl, Promedior, Sunovion, Theravance, Unity, UpToDate, Veracyte, Western Society of Allergy and Immunology. *Personal Benefits* >\$10,000: GlaxoSmithKline, Novartis, Nycomed/Takeda. *Shares:* none. *Non-Personal Interests:* none.

Nicolas Roche, Paris, France: *Personal Benefits* <\$10,000: AstraZeneca, Cipla, Mundipharma, Sandoz, Sanofi, SkyePharma, Takeda, Teva. *Personal Benefits* >\$10,000: Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis. *Shares:* none. *Non-Personal Interests* >\$10,000: Boehringer-Ingelheim, Novartis.

Roberto Rodriguez-Roisin, Barcelona Spain: *Personal Benefits* <\$10,000: AstraZeneca, Novartis, Pearl Therapeutics. *Shares:* none. *Non-Personal Interests* >\$10,000: Menarini.

Don Sin, Vancouver BC, Canada: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, Novartis. *Shares:* none. *Non-Personal Interests* >\$10,000: AstraZeneca, Boehringer-Ingelheim.

David Singh, Manchester UK: *Personal Benefits* <\$10,000: Respivert, Skypharma, Teva, Therevance, Verona. *Personal Benefits* >\$10,000: AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis. *Shares:* none. *Non-Personal Interests* >\$10,000: Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer, Respivert, Roche, Takeda, Verona.

Robert A. Stockley, Birmingham UK: *Personal Benefits* <\$10,000: CSL Behring, Boehringer-Ingelheim, Chiesi, Dyax, GlaxoSmithKline, Polyphor, Zealand. *Shares:* none. *Non-Personal Interests* >\$10,000: CSL Behring.

Claus Vogelmeier, Marburg Germany: *Personal Benefits* <\$10,000: Berlin Chemie, Chiesi, Grifols, Med Update, Mundipharma, Takeda *Personal Benefits* >\$10,000: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Omniamed. *Shares:* none. *Non-Personal Interests* >\$10,000: Grifols.

Jadwiga A. Wedzicha, London, UK: *Personal Benefits:* none. *Shares:* none. *Non-Personal Interests* >\$10,000: GlaxoSmithKline, Janssen, Takeda, Vifor Pharma.

All members confirmed no relation to, or income from, the tobacco industry.